Loading...
KTRA logo

Kintara Therapeutics, Inc.NasdaqCM:KTRA Stock Report

Market Cap US$12.8m
Share Price
n/a
1Y-95.0%
7D22.2%
1D-6.3%
Portfolio Value
​
View

Kintara Therapeutics, Inc.

NasdaqCM:KTRA Stock Report

Market Cap: US$12.8m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Kintara Therapeutics (KTRA) Stock Overview

A clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. More details

KTRA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Earnings have grown 2.4% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months compared to the US market

+ 1 more risk

KTRA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW501,452 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
501,452 investors already sharing narratives
View all narratives

Kintara Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Kintara Therapeutics
Historical stock prices
Current Share PriceUS$7.54
52 Week HighUS$160.51
52 Week LowUS$2.84
Beta0.81
1 Month Change12.72%
3 Month Change-14.56%
1 Year Change-94.98%
3 Year Change-99.54%
5 Year Change-99.23%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Seeking Alpha • Oct 19

Kintara soars 66% on pausing breast cancer study, to use cash for brain cancer trial

Kintara Therapeutics (NASDAQ:KTRA) said it paused its REM-001 program in cutaneous metastatic breast cancer (CMBC) to save cash. The money will be used to fund an ongoing international registrational study of VAL-083 to treat a type of brain cancer called glioblastoma (GBM), the company said in a statement on Wednesday. Kintara President and CEO Robert Hoffman expects results from the GBM AGILE study of VAL-083 at the end of 2023. By pausing the REM-001 program, Kintara expects to save ~$3M through 2023. "We will continue to explore ways to restart REM-001, including use of grants from applications currently under review to support the funding of the planned 15-patient CMBC study. Although this was a difficult decision, we believe saving approximately $3.0 million through calendar year 2023 is prudent given the current capital market conditions," said Hoffman. KTRA +65.73% to $0.17 premarket Oct. 19
Seeking Alpha • Sep 27

Kintara Therapeutics GAAP EPS of -$0.52

Kintara Therapeutics press release (NASDAQ:KTRA): FY GAAP EPS of -$0.52. At June 30, 2022, Kintara had cash and cash equivalents of approximately $11.8 million.
Seeking Alpha • Aug 03

Kintara Therapeutics rallies after $20M stock purchase deal with Lincoln Park Capital Fund

Kintara Therapeutics (NASDAQ:KTRA) stated Wednesday it has signed a direct equity purchase agreement for up to $20M investment with a Chicago-based institutional investor- Lincoln Park Capital Fund. Under the deal, Kintara will have the right, but not the obligation, to sell to LPC up to $20M of its shares over the period of 3-year agreement term. The company expects this commitment from LPC will provide financial flexibility and is aligned with Kintara's long-term strategy for value creation. KTRA shares jump 64% in pre-market, Wednesday.  Kintara said it intends to use net proceeds from the sale of its common stock to LPC for working capital and general corporate purposes, including development expenses for VAL-083 and REM-001.
Analysis Article • Apr 12

Kintara Therapeutics (NASDAQ:KTRA) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

KTRAUS BiotechsUS Market
7D22.2%4.0%-0.7%
1Y-95.0%42.5%20.3%

Return vs Industry: KTRA underperformed the US Biotechs industry which returned 26.7% over the past year.

Return vs Market: KTRA underperformed the US Market which returned 35.4% over the past year.

Price Volatility

Is KTRA's price volatile compared to industry and market?
KTRA volatility
KTRA Average Weekly Movement14.5%
Biotechs Industry Average Movement10.4%
Market Average Movement7.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: KTRA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: KTRA's weekly volatility has decreased from 25% to 15% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20091Robert Hoffmanwww.kintara.com

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd.

Kintara Therapeutics, Inc. Fundamentals Summary

How do Kintara Therapeutics's earnings and revenue compare to its market cap?
KTRA fundamental statistics
Market capUS$12.80m
Earnings (TTM)-US$8.50m
Revenue (TTM)n/a
0.0x
P/S Ratio
-49.4x
P/E Ratio

Is KTRA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KTRA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$8.50m
Earnings-US$8.50m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.15
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did KTRA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/17 07:21
End of Day Share Price 2024/10/17 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kintara Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group